Latest Paradigm Biocapital Advisors LP Stock Portfolio
$2.61Billion– No. of Holdings #35
Paradigm Biocapital Advisors LP Performance:
2024 Q2: -4.23%YTD: 1.91%2023: 7.59%
Performance for 2024 Q2 is -4.23%, and YTD is 1.91%, and 2023 is 7.59%.
About Paradigm Biocapital Advisors LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Paradigm Biocapital Advisors LP reported an equity portfolio of $2.6 Billions as of 30 Jun, 2024.
The top stock holdings of Paradigm Biocapital Advisors LP are NUVL, , ACLX. The fund has invested 13.3% of it's portfolio in NUVALENT INC and 8.9% of portfolio in ARGENX SE .
The fund managers got completely rid off IMMUNOCORE HLDGS PLC (IMCR), ALPINE IMMUNE SCIENCES INC (ALPN) and BICYCLE THERAPEUTICS PLC (BCYC) stocks. They significantly reduced their stock positions in VAXCYTE INC (PCVX), VIRIDIAN THERAPEUTICS INC (VRDN) and LEGEND BIOTECH CORP. Paradigm Biocapital Advisors LP opened new stock positions in MERUS N V (MRUS), JANUX THERAPEUTICS INC (JANX) and COGENT BIOSCIENCES INC (COGT). The fund showed a lot of confidence in some stocks as they added substantially to REVOLUTION MEDICINES INC (RVMD), Y-MABS THERAPEUTICS INC (YMAB) and IMMUNOVANT INC (IMVT).
The top stock holdings of Paradigm Biocapital Advisors LP are NUVL, , ACLX. The fund has invested 13.3% of it's portfolio in NUVALENT INC and 8.9% of portfolio in ARGENX SE .
The fund managers got completely rid off IMMUNOCORE HLDGS PLC (IMCR), ALPINE IMMUNE SCIENCES INC (ALPN) and BICYCLE THERAPEUTICS PLC (BCYC) stocks. They significantly reduced their stock positions in VAXCYTE INC (PCVX), VIRIDIAN THERAPEUTICS INC (VRDN) and LEGEND BIOTECH CORP. Paradigm Biocapital Advisors LP opened new stock positions in MERUS N V (MRUS), JANUX THERAPEUTICS INC (JANX) and COGENT BIOSCIENCES INC (COGT). The fund showed a lot of confidence in some stocks as they added substantially to REVOLUTION MEDICINES INC (RVMD), Y-MABS THERAPEUTICS INC (YMAB) and IMMUNOVANT INC (IMVT).
Paradigm Biocapital Advisors LP Equity Portfolio Value
Last Reported on: 14 Aug, 2024
Paradigm Biocapital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Paradigm Biocapital Advisors LP made a return of -4.23% in the last quarter. In trailing 12 months, it's portfolio return was 20.82%.
New Buys
| Ticker | $ Bought |
|---|---|
| merus n v | 119,512,000 |
| janux therapeutics inc | 65,534,900 |
| cogent biosciences inc | 30,553,200 |
| bridgebio pharma inc | 27,596,800 |
| erasca inc | 17,110,000 |
| verona pharma plc | 10,426,900 |
| alx oncology hldgs inc | 9,500,900 |
| perspective therapeutics inc | 9,169,330 |
New stocks bought by Paradigm Biocapital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| revolution medicines inc | 80.42 |
| y-mabs therapeutics inc | 73.29 |
| immunovant inc | 70.56 |
| kura oncology inc | 44.78 |
| ascendis pharma a/s | 30.78 |
| immatics n.v | 21.39 |
| cullinan therapeutics inc | 14.45 |
| disc medicine inc | 13.17 |
Additions to existing portfolio by Paradigm Biocapital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| vaxcyte inc | -49.42 |
| viridian therapeutics inc | -42.43 |
| legend biotech corp | -39.29 |
| crinetics pharmaceuticals in | -19.57 |
| xenon pharmaceuticals inc | -17.77 |
| tarsus pharmaceuticals inc | -14.95 |
| sarepta therapeutics inc | -12.13 |
| arvinas inc | -6.76 |
Paradigm Biocapital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| autolus therapeutics plc | -40,996,600 |
| bicycle therapeutics plc | -80,844,300 |
| caribou biosciences inc | -11,167,300 |
| alpine immune sciences inc | -84,082,900 |
| immunocore hldgs plc | -116,166,000 |
| zentalis pharmaceuticals inc | -14,891,900 |
| agios pharmaceuticals inc | -11,696,000 |
| cargo therapeutics inc | -3,302,440 |
Paradigm Biocapital Advisors LP got rid off the above stocks
Sector Distribution
Paradigm Biocapital Advisors LP has about 78.5% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 78.5 |
| Others | 21.5 |
Market Cap. Distribution
Paradigm Biocapital Advisors LP has about 5.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 51.9 |
| UNALLOCATED | 21.5 |
| SMALL-CAP | 20.2 |
| LARGE-CAP | 5.7 |
Stocks belong to which Index?
About 64.1% of the stocks held by Paradigm Biocapital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 64.1 |
| Others | 35.9 |
Paradigm Biocapital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP has 35 stocks in it's portfolio. About 64.6% of the portfolio is in top 10 stocks. ACLX proved to be the most loss making stock for the portfolio. SRPT was the most profitable stock for Paradigm Biocapital Advisors LP last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 8.13 | 3,848,100 | 212,376,000 | added | 0.79 | ||
| AGIO | agios pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALPN | alpine immune sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALXO | alx oncology hldgs inc | 0.36 | 1,575,600 | 9,500,900 | new | |||
| ARVN | arvinas inc | 2.48 | 2,438,150 | 64,903,500 | reduced | -6.76 | ||
| AUTL | autolus therapeutics plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BBIO | bridgebio pharma inc | 1.06 | 1,089,490 | 27,596,800 | new | |||
| BCYC | bicycle therapeutics plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CERE | cerevel therapeutics hldng i | 3.65 | 2,330,510 | 95,294,500 | unchanged | 0.00 | ||
| CGEM | cullinan therapeutics inc | 1.03 | 1,542,800 | 26,906,500 | added | 14.45 | ||
| CMPS | compass pathways plc | 0.54 | 2,335,930 | 14,109,000 | reduced | -2.3 | ||
| COGT | cogent biosciences inc | 1.17 | 3,624,340 | 30,553,200 | new | |||
| CRBU | caribou biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRNX | crinetics pharmaceuticals in | 4.31 | 2,513,300 | 112,571,000 | reduced | -19.57 | ||
| ERAS | erasca inc | 0.66 | 7,250,000 | 17,110,000 | new | |||
| EWTX | edgewise therapeutics inc | 1.60 | 2,325,450 | 41,881,300 | reduced | -4.94 | ||
| IMCR | immunocore hldgs plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IMVT | immunovant inc | 1.38 | 1,362,830 | 35,978,600 | added | 70.56 | ||
| JANX | janux therapeutics inc | 2.51 | 1,564,450 | 65,534,900 | new | |||
| KURA | kura oncology inc | 3.58 | 4,539,380 | 93,465,900 | added | 44.78 | ||